Telephus Biosciences

Telephus Biosciences is a biotechnology company dedicated to developing novel immunotherapies for the treatment and prevention of life-threatening bacterial infections. The company's primary focus is on addressing Staphylococcus aureus (S. aureus) infections, including multi-drug resistant strains like MRSA, which pose a significant global health threat. Telephus utilizes a proprietary platform to develop high-affinity monoclonal antibodies that target multiple virulence factors simultaneously, effectively neutralizing the pathogen's ability to evade the immune system and cause tissue damage. By focusing on passive immunization, the company aims to provide effective alternatives or adjuncts to traditional antibiotics. Their research is rooted in foundational work originating from MassBiologics at the University of Massachusetts Medical School.